Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

FAT jabs could harm mum and baby if taken too close to pregnancy, a study suggests. Women who used the GLP-1 injections, such ...

Why Am I Not Losing Weight on Wegovy®? How to Get Results Key takeaways: Not losing weight on Wegovy® could be due to dose, ...

In the first quarter of 2018, there were less than five postpartum GLP-1 prescriptions, but by the second quarter of 2022, the number rose to 34 per 10,000 and sharply increased to 173 per 10,000 in ...

People buying the peptide retatrutide online could suffer from side-effects ranging from nausea to pancreatitis ...

The results show the treatment's potential to mitigate GLP-1 induced nausea and vomiting, which are key factors for those who stop using weight-loss drugs, Vanda Chief Executive Mihael Polymeropoulos ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

The results from the two trials of early-stage patients, called EVOKE and EVOKE+, are another setback for the Danish drugmaker and new CEO Mike Doustdar, which had seen booming success, driven by ...

AFTER regularly raiding the snack drawer for crisps and chocolate, Jack Adams became a target for cruel playground bullies as ...

Stock futures are pointing to a higher open after a volatile stretch of trading last week, as traders price in a higher likelihood that the Federal Reserve will cut interest rates next month. Here's ...

Oral semaglutide—a key ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs ...